Copy to clipboard 
DiFusion entered into a licensing agreement for its’ ZFUZE immunomodulatory biomaterial with Genesis Medical Plastics to market and sell DiFusion’s ZFUZE Immunomodulatory polymer and stock shapes made from the polymer in Asia and the European Union. ZFUSE is an ASTM F2026 compliant material suitable for long-term human implantation.
The strategic partnership involves a combination of upfront financial participation and a long-term revenue sharing agreement.
Recent postmarket studies have shown ZFUZE superiority for spinal fusions, demonstrating a 93.4% fusion rate at 7 months, while comparative peer-reviewed studies post an average fusion rate of just 68% at 12 months.
Genesis initially will offer ZFUSE polymer and a range of ZFUZE machinable shapes and expand the product line to other forms as new requirements and applications are identified.
According to Steven Quance, Genesis President, “We have been the machinable shapes provider for DiFusion’s ZFUSE through many years of studies, trials and approvals. We have long recognized that ZFUZE is a game-changing material technology in implantable polymers and we are excited to be working closely with DiFusion to bring their products to our international customers.”
Source: DiFusion
